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Plasma ﬁbrinogen measurement is a routine laboratory procedure
commonly performed on automated coagulation analysers. Its
determination is quantitative, not quantitative. Yet, a lack of
precision has been an issue for ﬁbrinogen measurement. A control
material derived from plasma comprises many proteins, inhibitors
and fatty acids, any or all of which can interfere in the ﬁbrinogen
assay. This study has attempted to develop a quality control
material using puriﬁed human ﬁbrinogen and has compared
measurement precision between both puriﬁed and plasma materials.
Puriﬁed ﬁbrinogen was prepared using Cohn fraction 1 and glycine
precipitation. Puriﬁed ﬁbrinogen clottability was greater than
95%, with no main plasma proteins, lipids or ﬁbrinogen
degradation products observed. Two puriﬁed control materials were
lyophilized at normal (2.30gl
 1) and abnormal (1.20gl
 1)
levels of ﬁbrinogen concentration. Precision was evaluated using
a liquid-type reagent, Thrombocheck Fib(L), on automated
coagulation analysers. Coeﬃcient of variation for within-run,
intraday and between-day precision of the puriﬁed materials
was 0.7–3.5%. In comparison, the coeﬃcient of variation for
plasma materials ranged from 1.2 to 5.3%. These results suggest
that materials prepared from puriﬁed ﬁbrinogen can be useful to
laboratory quality control by improving overall precision of
ﬁbrinogen measurement and are applicable to automated coagula-
tion analysers.
Introduction
Fibrinogen is a heterogeneous glycoprotein of molecular
weight (MW) 340000 and consisting of three pairs of
polypeptide chains (Aa,Bb,g) [1]. Plasma ﬁbrinogen
measurement is obtained by a screening coagulation test
and many laboratories in Japan use the Clauss method
[2]. Clinical studies have shown that an increased level of
plasma ﬁbrinogen is a strong predictor of atherosclerotic
disease [3–5]. The diﬀerence between ﬁbrinogen con-
centrations obtained by the Clauss method and those
obtained by clottability assays is signiﬁcantly correlated
to the high molecular weight (HMW) ﬁbrinogen of
patient samples during an acute-phase reaction [6].
A wide range of ﬁbrinogen measurement methods have
been described, including biological, immunological,
gravimetric and prothrombin time-derived [2,7–9].
Some manufacturers suggest calibration against the
World Health Organization-prescribed international
standard [10], which was based on the Clauss method
and a recommended gravimetric assay (Jacobsson).
Thus, a world-wide standardization of ﬁbrinogen mea-
surement has already been established.
In Japanese laboratories, an annual survey conducted by
the Japan Medical Association (JMA) examines test
performance in haematology, chemistry and immunology
and its aim is improvement of quality control. In the
Japanese market, multicontrol materials for prothrombin
time, activated partial thromboplastin time and ﬁbrino-
gen assay are commercially available; however, as they
are artiﬁcially prepared from human plasma with various
concentrations of ﬁbrinogen, they are not useful for
ﬁbrinogen measurement. This is reﬂected by the poor
record of accuracy and precision according to surveys
conducted during the past 10 years [11]. Other current
problems concerning ﬁbrinogen measurement have been
reported in various surveys [12]. Recently, the Hematol-
ogy Subcommittee of the Standardization Committee of
the Japan Society of Laboratory Medicine (JSLM) has
documented a standardized method of ﬁbrinogen mea-
surement in plasma and established a reliable ﬁbrinogen
standard for both the Clauss method and turbidimetric
immunoassay [13,14]. However, a material that pro-
duces precision and is suitable to quality control has yet
to be proposed. A study was therefore undertaken to
develop such a quality control material, having homo-
geneous composition, with no turbidity and reference
material-like characteristics, in order to improve overall
precision of plasma ﬁbrinogen measurement.
The objective was to compare precision of puriﬁed mate-
rials and plasma materials for plasma ﬁbrinogen tests
using the Clauss method and to propose a quality control
material suitable for plasma ﬁbrinogen measurement.
Experimental
Source plasma
Plasma collected from 56 healthy donors was obtained
from Alpha Therapeutic Corporation (Los Angeles,
USA). Pooled plasma was stored at –80 C before pre-
paration.
Plasma materials
For normal control plasma, pooled plasma was used.
Abnormal control plasma was prepared at half the
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79concentration of pooled plasma and buﬀered with Owren
veronal buﬀer. The two plasma materials were then
lyophilized.
Puriﬁed ﬁbrinogen materials
Cohn fraction 1 [15] prepared from pooled human
plasma was suspended in 55mmoll
 1 citrate buﬀer (pH
6.4) containing 100mmoll
 1 sodium chloride and
12Uml
 1 unfractionated heparin in an ice bath and
centrifuged. The supernatant was treated with a solvent
detergent of 1% (v/v) Tween 80 and 0.3% (v/v)
Tri-n-butyl phosphate (TNBP) (both Kishida Chemical,
Osaka, Japan) for virus inactivation [16]. To the treated
solution was added 1.8moll
 1 glycine. The solution was
then centrifuged. This process was repeated twice and
the ﬁnal precipitates collected [17]. The precipitated
ﬁbrinogen was dissolved in 20mmoll
 1 citrate buﬀer
(pH 6.8) containing 100mmoll
 1 sodium chloride and
passed through a lysine Sepharose column (2 15cm,
10ml; Amersham Pharmacia Biotech, Tokyo, Japan) to
remove plasminogen [18] (ﬁgure 1). Two lyophilized
puriﬁed ﬁbrinogen-produced materials of diﬀerent
concentration (2.30 and 1.20gl
 1) were prepared in a
matrix of 2.0% (w/v) protease-free bovine serum albu-
min (BSA) (Intergen Corporation, Georgia, USA) in
20mmoll
 1 citrate buﬀer (pH 6.8) containing
100mmoll
 1 sodium chloride.
Identiﬁcation of ﬁbrinogen
The purity of the ﬁbrinogen was evaluated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (Bio-Rad, Tokyo, Japan). Coomassie
brilliant blue (CBB) was used for protein staining. For
reduced condition, a sample solution was mixed with
1% (w/v) SDS solution at 1:4, then left standing for
30min at 56 C, which was followed by the addition
of 5% (w/v) 2-mercaptoethanol, then applied on 7.5%
polyacrylamide gel containing 0.1% (w/v) SDS. For
non-reduced condition, a sample solution was applied
on 4% polyacrylamide gel containing 0.1% (w/v) SDS.
Immunoblotting was carried out with rabbit antiﬁbrino-
gen polyclonal antibody and a horseradish peroxidase
conjugated goat anti-rabbit IgG antibody (both Dako-
Japan, Kyoto, Japan). Clottablility of the puriﬁed
ﬁbrinogen was measured by the Laki method [19] using
a UV-160 spectrophotometer (Shimadzu Corporation,
Kyoto, Japan).
Fibrinogen measurement
Thrombocheck Fib (L) (Sysmex Corporation, Kobe,
Japan) [20] is a liquid-type reagent for use with the
Clauss method, and was employed for ﬁbrinogen mea-
surement. The precision of within-run (n¼20), intraday
(n¼5) and between-day (n¼20) measurements was
examined by CA-1500 (Sysmex), Coagrex-700 and
Coagrex-800 (Shimadzu) [21] automated coagulation
analysers. The ﬁbrinogen standard used in the assay
was a commercial product (Fib STD; Sysmex), cali-
brated against the international reference standard pre-
scribed by the WHO (98/612) [10], according to NCCLS
procedures [22].
Comparison of precision of ﬁbrinogen fractions in the
preparation process
Crude fractions of the Cohn I, and ﬁrst, second and third
precipitates were prepared from 10 random plasma
samples during the puriﬁcation process described above.
Each fraction was completely dissolved in 20mmoll
 1
citrate buﬀer (pH 6.8) containing 100mmoll
 1 sodium
chloride at 37 C and adjusted to 2.30gl
 1 ﬁbrinogen
Fresh plasma
↓ ↓
Cohn fraction 1
↓
Virus inactivation at 30°C for 1hr
(treated with 1% v/v Tween 80 and 0.3% v/v TNBP) 
↓
Glycine precipitation 
(repeat 3 times)
↓
↓
Removal of plasminogen 
(lysine-Sepharose column) 
Sterile filtration 
 
Purified fibrinogen solution
↓
↓
Lyophilisation 
(about 2.30 g/L and 1.20 g/L) 
Figure 1. Fibrinogen puriﬁcation procedure.
80
M. Okuda et al. Quality control material for plasma fibrinogen testconcentration using the Clauss method, and measured
for reproducibility (n¼20) on the Coagrex-800.
Residual contaminant analysis
Analysis was performed for detection of contaminant
plasma proteins (antithrombin, plasminogen, antiplas-
min, coagulation factors), lipids (cholesterol, triglyceride,
low density lipoprotein cholesterol (LDL), high density
lipoprotein cholesterol (HDL)), turbidity (at 660nm)
and ﬁbrinogen degradation products (FDP) in the puri-
ﬁed ﬁbrinogen solution and pooled plasma. The puriﬁed
ﬁbrinogen solution was adjusted in a concentration
of 2.3gl
 1 as a clottable protein using the Jacobsson
method [8]. The following reagents (all Sysmex) were
used: L-System AT III, PLG and APL; Thrombocheck
Factors II, V, VII, X, VIII, IX, XI and XII for
coagulation factors; T-CHO-K, TG-KL, HDLC-KL
and LDL-C-KL for lipids; latex test BL-2 FDP for FDP
assay. Turbidity for each fraction solution was prepared
according to the Jacobson method [8] and measured at
660nm wavelengths in a 1-cm cuvette using the UV-160
spectrophotometer.
Eﬀect of contaminated plasminogen
A 100-ml aliquot of urokinase (1000Uml
 1) (Mitsubishi
Pharma Corporation, Osaka, Japan) solution was added
to 5ml 0.2% (w/v) puriﬁed ﬁbrinogen solution, both
before and after passage through the lysine-Sepharose
column, and incubated at 37 C for 0, 6 or 18h according
to a modiﬁed procedure [18]. The reaction was stopped
by addition of 1000ATUml
 1 aprotinin (Penthapharm-
Japan, Tokyo, Japan) and one aliquot was submitted
to SDS-PAGE analysis.
Stability after reconstitution of materials
Two quality control materials were lyophilized for
stabilization, then reconstituted and stored at 11 C for
0, 1, 2, 4, 6, 8 or 12h. Their stability after reconstitution
was tested by measuring ﬁbrinogen concentration on the
Coagrex-800.
Results
Fibrinogen purity
The clottability of the puriﬁed ﬁbrinogen was 95%
according to the Laki method [19] (table 1). The
appearance of the puriﬁed ﬁbrinogen solution was clear.
Electrophoresis patterns under non-reducing conditions
by CBB staining showed one broad band at 340kDa,
and those under reducing conditions showed its three
subunits, Aa-, Bb- and g-chains (ﬁgure 2). No FDP were
observed by SDS-PAGE.
Precision comparison of ﬁbrinogen fractions in the preparation
The precision of within-run measurements (n¼20) of
ﬁbrinogen fractions obtained from the ﬁrst, second and
third precipitate fractions was better than that obtained
from plasma or Cohn fraction 1 (ﬁgure 3).
(A) (B)
non-reduced reduced non-reduced       reduced
340 kDa
Aα    65 kDa
Ββ  55 kDa
γ  47 kDa
Figure 2. SDS-PAGE patterns of puriﬁed ﬁbrinogen. (A) CBB stain: electrophoresis, 60V for 2.5h; gel, 7.5% polyacrylamide; buﬀer,
25mM Tris and 192mM glycine containing 0.02% (w/v) SDS buﬀer (pH 7.5). (B) Western blot: membrane, PVDF membrane;
buﬀer, 25mM Tris and 192mM glycine containing 20% (v/v) methanol and 0.02% (w/v) SDS buﬀer (pH 8.3).
Table 1. Fibrinogen purity.
Before
a
(A)
After
a
(B)
Purity
b
(A–B)/A
0.491 0.003 0.022 0.001 95%
aOptimal density of puriﬁed ﬁbrinogen solution at 280nm and
the supernatant ﬂuid after removing a thrombin-induced clot.
bPurity expressed as percentage of clottable proteins.
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Although neither plasma proteins (e.g. antithrombin,
plasminogen, antiplasmin, coagulation factors, FDP)
nor lipid contaminants (e.g. cholesterol, triglyceride,
LDL, HDL) were observed in the puriﬁed ﬁbrinogen
material, contaminants were detected in the plasma
material (table 2). The turbidity measured at 660nm
of the glycine-precipitated ﬁbrinogen fractions was close
to the detection limit (less than optical density 0.01).
Total precision evaluation
Coeﬃcient of variation for within-run and between-day
precision (n¼20) of the puriﬁed materials at normal
(2.30gl
 1) and abnormal (1.20gl
 1) levels was 1.7–
3.5%, while that for plasma materials was 3.1–5.3%
(tables 3 and 4). Intraday (n¼5) CVs for puriﬁed
materials and plasma materials were 0.7–1.6 and 1.2–
3.0%, respectively (table 5).
Stability
After incubation of the puriﬁed ﬁbrinogen with human
urokinase under appropriate conditions for over 18h at
37 C, no evidence of the subunits of FDP after treatment
on the lysine-Sepharose column was observed using SDS-
PAGE (ﬁgure 4). The non-treated ﬁbrinogen solution,
however, was clearly degraded. After reconstitution of
the lyophilized material, the materials prepared showed
good stability at 11 C for up to 12h on the Coagrex-800
(ﬁgure 5).
Discussion
After preparing control materials derived from a plasma
source and from puriﬁed ﬁbrinogen, their measurement
precision was compared using automated coagulation
analysers, the CA-1500, Coagrex-700 and Coagrex-800,
all of which were equipped with light-scattering optical
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Figure 3. Comparison of precision of ﬁbrinogen fractions in the preparation process. The coeﬃcient of variation (n¼20) of each fraction
obtained from 10 random plasma samples was examined using Coagrex-800. Bars are the mean of CV (%).
Table 2. Comparison of contaminants.
Contaminant
Preparation process
Pooled plasma Cohn fraction 1
Precipitate
123
Antithrombin (%) 103 8 6 ND ND
Plasminogen (%) 96 13 9 3 2
Antiplasmin (%) 96 11 4 2 ND
Intrinsic factors (%) 95 21 36 11 9 3N DN D
Extrinsic factors (%) 102 19 11 76  2N DN D
FDP (mgl
 1) 3.2 1.2 ND ND ND
Cholesterol (mmoll
 1) 3.13 0.34 0.08 ND ND
Triglyceride (gl
 1) 1.04 0.09 0.02 ND ND
LDL (mgl
 1) 980 50 ND ND ND
HDL (mgl
 1) 660 50 ND ND ND
Turbidity (660nm) 1.25 0.94 0.18 0.03 0.01
ND, not detected.
82
M. Okuda et al. Quality control material for plasma fibrinogen test(A) (B)
Aα   65 kDa
Bβ   55 kDa
γ  47 kDa
1 2 3 1  2 3
33 kDa
19 kDa
Figure 4. SDS-PAGE of puriﬁed ﬁbrinogen. (A) Urokinase-treated puriﬁed ﬁbrinogen before passage through lysine-Sepharose column.
(B) Urokinase-treated puriﬁed ﬁbrinogen after passage through the column. Lanes 1, before; 2, 6h after; 3, 18h after incubation with
urokinase. Electrophoresis, 60V for 3.0h; gel, 5–20% gradient polyacrylamide gel; buﬀer, 25mM Tris and 192mM glycine containing
0.02% (w/v) SDS buﬀer (pH 7.5); stain, CBB.
Table 3. Within-run precision.
Instrument
Puriﬁed material Plasma material
Normal Abnormal Normal Abnormal
Mean CV(%) Mean CV(%) Mean CV(%) Mean CV(%)
CA-1500 2.28 2.4 1.19 2.5 2.31 3.8 1.21 4.6
Coagrex-700 2.33 1.7 1.21 2.4 2.39 3.1 1.23 5.0
Coagrex-800 2.29 2.3 1.23 2.8 2.32 3.3 1.26 4.3
Data are means expressed as ﬁbrinogen concentration (gl
 1) and replicated 20 times.
Table 4. Between-day precision.
Instrument
Puriﬁed material Plasma material
Normal Abnormal Normal Abnormal
Mean CV(%) Mean CV(%) Mean CV(%) Mean CV(%)
CA-1500 2.27 2.5 1.16 3.2 2.30 3.6 1.19 4.2
Coagrex-700 2.29 2.2 1.17 2.9 2.36 3.2 1.24 5.3
Coagrex-800 2.33 2.4 1.20 3.5 2.34 3.5 1.22 4.2
Data are means expressed as ﬁbrinogen concentration (gl
 1) and replicated 20 times.
Table 5. Intraday precision.
Instrument
Puriﬁed material Plasma material
Normal Abnormal Normal Abnormal
Mean CV(%) Mean CV(%) Mean CV(%) Mean CV(%)
CA-1500 2.23 0.9 1.17 1.6 2.33 1.6 1.24 2.3
Coagrex-700 2.36 0.7 1.22 1.0 2.34 1.2 1.27 3.0
Coagrex-800 2.32 0.7 1.21 0.9 2.36 1.8 1.25 2.2
Data are means expressed as ﬁbrinogen concentration (gl
 1) and replicated ﬁve times.
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sion to plasma material for all within-run, within-day
and between-day measurements. Pooled plasma consists
of plasma proteins (antithrombin, plasminogen, antiplas-
min, coagulation factors) and lipid contaminants (such as
cholesterol, triglyceride, LDL, HDL). It was assumed
that these contaminants might aﬀect the precision of
ﬁbrinogen measurement for the Clauss method. In the
preparation step, the Cohn fraction 1 was yielded by
ethanol precipitation, and the ﬁbrinogen fraction was
puriﬁed by glycine precipitation combining a virus-
inactivated treatment by SDS denaturation and lysine-
Sepharose aﬃnity column chromatography to eliminate
contaminating plasminogen. During a virus-inactivation
step, detergents (Tween 80 and TNBP) can eliminate
contaminants derived from lipids completely. Residual
lipids and turbidity were found in the glycine-precipitate,
but at lower concentrations than those found in Cohn
fraction 1. However, these contaminants and turbidity
were detected at much higher concentrations in pooled
plasma (table 1). Thus, the purity of the puriﬁed
ﬁbrinogen was more than 95% as a clottable protein,
and no other plasma proteins or lipid contaminants were
observed. It was also demonstrated that the puriﬁed
material solution after reconstitution was clear and its
optical density at 315nm was less than 10% of that
at 280nm according to the Jacobsson method [8].
These results suggest that turbidity and lipid or other
protein contaminants may aﬀect the precision of
ﬁbrinogen measurement; clearly, a contaminant-free
material is better applied for coagulation analysers.
In addition, a homogeneous reaction between ﬁbrinogen
(in the source material) and thrombin (in the reagent)
may have contributed to good precision in both normal-
and abnormal-level materials when using puriﬁed
ﬁbrinogen. Additionally, the safety of puriﬁed ﬁbrinogen
were conﬁrmed when tests for HbsAg and antibodies
to HIV-1, HIV-2 and HCV were all negative (data not
shown).
In conclusion, the puriﬁed material rendered precision
superior to that of plasma material when using the Clauss
method. These characteristics make it well suited for
daily quality control. Moreover, it proved free of
contaminants, and was highly stable and applicable to
commonly used fully automated coagulation analysers.
As such, the puriﬁed material may be helpful in improv-
ing the precision of ﬁbrinogen measurement in the
clinical laboratory.
References
1. Nieuwenhuizen,W . ,Eur. Heart J., 16 (1995), 6.
2. Clauss,V. A., Acta Haematol., 17 (1957), 237.
3. Henrich, J., Balleisn, L., Schulte, H., Assmann, G. and Van De
Loo, J., Arteriosclerosis and Thrombosis, 14 (1994), 54.
4. Reganon, E., Vila, V., Ferrando, F., Martinez-Sales, V., Fayos,
L., Ruano, M. and Aznar, J., Thromb. Haemost., 82 (1999), 1403.
5. Woodward,M.,Lowe,G.D.,Rumley,A. andTunstall-Pedoe,H.,
Eur. Heart J., 19 (1998), 55.
6. Jensen, T., Halvorsen, S., Godal, H. C., Sandset, P. M. and
Skjoonsberg, O. H., Thromb. Res., 100 (2000), 397.
7. Hoegee-de Nobel, E., Voskuilen, M., Briet, E., Brommer, E. J.
and Nieuwenhuizen,W . ,Thromb. Haemost., 22 (1988), 4158.
8. Jacobsson, K., Scand. J. Clin. Lab. Invest., 7 (1955), 1.
9. Mackie,J.,Lawrie,A.S.,Kitchen,S.,Gaffney,P.J.,Howarth,D.,
Lowe, G. D., Martin, J., Purdy, G., Rigsby, P. and Rumley, A.,
Thromb. Haemost., 87 (2002), 997.
10. Whitton, C. M., Sands, D., Hubbard, A. R. and Gaffney, P. J.,
Thromb. Haemost., 84 (2000), 258.
11. Tatsumi, N., Okuda, M., Kondo, H. and Takubo, T., Proceedings
of Asian Society for Quality Assurance in Laboratory Medicine (2003) (in
press).
12. Hirai, N., Tatsumi, N., Hino, M., Yamane, T. and Ohta, K.,
Osaka City Med. J., 44 (1988), 55.
13. Tatsumi, N., Rinsyou Byouri, 49 (2001), 1273.
14. Tatsumi, N., Rinsyou Byouri, 49 (2001), 1280.
15. Cohn, F. J., Strong, L. E., Hughes, W. L., Jr, Mulfird, D. J.,
Ashworth, J. N., Melin, M. and Taylor, H. L., J. Am. Chem.
Soc., 68 (1946), 459.
16. Uemura, Y., Yang, Y. H., Heldebrant, C. M., Takechi, K. and
Yokoyama, K. Vox Sang, 67 (1994), 337.
17. Okuda, M., Uemura, Y., Naka, K. and Tatsumi, N., Clin. Lab.
Hematol., 25 (2003), 167.
0.80
1.20
1.60
2.00
2.40
2.80
0 1 2 3 6 8 12 18
Duration after reconstitution (h)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
g
 
l
-
1
)
Figure 5. Stability of puriﬁed materials after reconstitution. Fibrinogen measurement was performed using Thrombocheck Fib (L) on
Coagrex-800.  , Normal (2.2gl
 1); g, Abnormal (1.2gl
 1).
84
M. Okuda et al. Quality control material for plasma fibrinogen test18. Matsuda, M., Iwanaga, S. and Nakamura,S .Thromb. Res., 1
(1972), 619.
19. Laki, K., Arch. Biochem. Biophys., 32 (1951), 317.
20. Kikukawa,N.,Okuda, M.,Minami,S.,Ohta,Y. and Uemura, Y.,
Clin. Chem., 47 (2001), A167.
21. Okuda, M., Kikukawa, N., Fujikawa, Y., Uemura, Y. and
Yokoyama, K., Clin. Chem., 46 (2000), A135.
22. National Committee for Clinical Laboratory Standardiza-
tion (NCCLS). Procedure for the Determination of Fibrinogen in Plasma:
Approved Guideline. NCCLS H30-A2 (Wayne: NCCLS, 2001).
85
M. Okuda et al. Quality control material for plasma fibrinogen test